journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://www.readbyqxmd.com/read/28649691/gluten-and-aluminum-content-in-synthroid-%C3%A2-levothyroxine-sodium-tablets
#1
Ramon Espaillat, Michael F Jarvis, Cory Torkelson, Brent Sinclair
INTRODUCTION: Inquiries from healthcare providers and patients about the gluten and aluminum content of Synthroid(®) (levothyroxine sodium tablets) have increased. The objective of this study was to measure and evaluate the gluten content of the raw materials used in the manufacturing of Synthroid. Additionally, this study determined the aluminum content in different strengths of Synthroid tablets by estimating the amount of aluminum in the raw materials used in the manufacturing of Synthroid...
June 26, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28646394/the-antihypertensive-efficacy-of-the-triple-fixed-combination-of-perindopril-indapamide-and-amlodipine-the-results-of-the-petra-study
#2
György Ábrahám, Csaba András Dézsi
INTRODUCTION: The etiology of essential hypertension is multifactorial. Therefore, treatment with combinations of antihypertensive agents acting on multiple targets is necessary for successful therapy in the majority of patients. According to the experience and clinical data accumulated so far, combination therapy with three agents from different pharmacological classes is required in approx. 30% of patients in order to achieve long-term blood pressure control. The primary objective of the PETRA study was to evaluate the efficacy of blood pressure (BP) control with once daily administration of the different dosage strengths of the once-daily, triple fixed combination of perindopril, indapamide, and amlodipine...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28646393/the-changing-landscape-of-alopecia-areata-the-therapeutic-paradigm
#3
REVIEW
Yael Renert-Yuval, Emma Guttman-Yassky
Alopecia areata (AA), a prevalent inflammatory cause of hair loss, lacks FDA-approved therapeutics for extensive cases, which are associated with very poor rates of spontaneous hair regrowth and major psychological distress. Current treatments for severe cases include broad immune-suppressants, which are associated with significant adverse effects, precluding long-term use, with rapid hair loss following treatment termination. As a result of the extent of the disease in severe cases, topical contact sensitizers and intralesional treatments are of limited use...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28646392/the-changing-landscape-of-alopecia-areata-the-translational-landscape
#4
REVIEW
Etienne C E Wang, Angela M Christiano
Recent genetic and preclinical studies have increased our understanding of the immunopathogenesis of alopecia areata (AA). This has allowed expedited development of targeted therapies for the treatment of AA, and a paradigm shift in our approach and understanding of autoimmunity and the hair follicle. The synergy between preclinical studies, animal models, and translational studies has led to unprecedented advances in the treatment options for AA, ultimately benefiting patients who have had little recourse...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28646391/the-changing-landscape-of-alopecia-areata-an-introduction
#5
REVIEW
George Han
Alopecia areata is an extremely common autoimmune condition affecting hair. Severe forms of alopecia areata exist, with existing treatments consisting of systemic immunosuppressants with numerous side effects. Recently, breakthroughs have been made in both understanding the pathogenesis of alopecia areata and the treatment thereof, which hold the promise of being able to target severe cases of alopecia areata with more efficacy and better tolerability. This article serves as an introduction to review papers from two of the leading researchers in the field of alopecia areata...
June 23, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28631218/an-observational-study-of-the-effect-of-levodopa-carbidopa-intestinal-gel-on-activities-of-daily-living-and-quality-of-life-in-advanced-parkinson-s-disease-patients
#6
Rejko Krüger, Paul Lingor, Triantafyllos Doskas, Johanna M L Henselmans, Erik H Danielsen, Oriol de Fabregues, Alessandro Stefani, Sven-Christian Sensken, Juan Carlos Parra, Koray Onuk, Ashley Yegin, Angelo Antonini
INTRODUCTION: Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) by percutaneous endoscopic gastrojejunostomy (PEG-J) in advanced Parkinson's disease (PD) patients reduces variability in plasma levels, providing better control of motor fluctuations ("on" and "off" states). The MONOTREAT study assessed the effect of LCIG on activities of daily living, motor and non-motor symptoms, and quality of life in advanced PD patients. METHODS: This prospective, observational study included patients with advanced, levodopa-responsive PD with either 2-4 h of "off" time or 2 h of dyskinesia daily...
June 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28631217/24-month-open-label-teriparatide-once-weekly-efficacy-research-trial-examining-bone-mineral-density-in-subjects-with-primary-osteoporosis-and-high-fracture-risk
#7
Toshitsugu Sugimoto, Masataka Shiraki, Masao Fukunaga, Hiroshi Hagino, Teruki Sone, Tetsuo Nakano, Hideaki Kishimoto, Masako Ito, Hideki Yoshikawa, Mitsukazu Kishida, Chika Irie, Toshitaka Nakamura
INTRODUCTION: To clarify the additional efficacy and safety benefits of 24 months' treatment with the once-weekly formulation of teriparatide, which is currently used for 72 weeks. METHODS: This was a multicenter, open-label, single-arm study conducted in Japan. Subjects who were 65 years or older with prevalent vertebral fractures received once-weekly subcutaneous injection of 56.5 μg teriparatide for 24 months. The main outcome measure was percentage change from baseline in lumbar (L2-L4) BMD measured by dual-energy X-ray absorptiometry...
June 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28631216/safety-and-tolerability-of-empagliflozin-in-patients-with-type-2-diabetes-pooled-analysis-of-phase-i-iii-clinical-trials
#8
Sven Kohler, Cordula Zeller, Hristo Iliev, Stefan Kaspers
INTRODUCTION: We characterized the safety and tolerability of empagliflozin in patients with type 2 diabetes (T2DM) randomized 1:1:1 to placebo, empagliflozin 10 mg, or empagliflozin 25 mg in clinical trials. METHODS: Pooled data were analyzed from patients with T2DM treated with placebo (N = 4203), empagliflozin 10 mg (N = 4221), or empagliflozin 25 mg (N = 4196) in 15 randomized phase I-III trials plus four extension studies. Adverse events (AEs) were assessed descriptively in participants who took at least one dose of study drug...
June 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28631215/comment-on-rosenberg-j-et-al-deep-neuromuscular-blockade-improves-laparoscopic-surgical-conditions-a-randomized-controlled-study
#9
LETTER
Michiel C Warlé, Albert Dahan
No abstract text is available yet for this article.
June 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28625003/when-science-is-not-enough-a-framework-towards-more-customer-focused-drug-development
#10
REVIEW
Nektarios Oraiopoulos, William C N Dunlop
INTRODUCTION: The purpose of this study was to identify the key barriers to a customer-focused drug development process and develop a comprehensive framework to overcome them. METHODS: The paper draws on existing literature, both academic and practitioner, across a range of disciplines (innovation management, marketing, organizational behavior, behavioral economics, health economics, industry reports). On the basis of this extensive review, a conceptual framework is developed that offers concrete suggestions on how organizations can overcome the barriers and enable a more customer-focused development process...
June 17, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28597355/minimal-device-encrustation-on-vesair-intravesical-balloons-in-the-treatment-of-stress-urinary-incontinence-analysis-of-balloons-removed-from-women-in-the-solect-trial
#11
Gommert A van Koeveringe, Stefan De Wachter, Jack M Zuckerman, Giovanni Tommaselli, Michel J de Wildt, Karel C M Everaert, Dirk P J Michielsen, Jean-Jacques Wyndaele
INTRODUCTION: Encrustation of urinary biomaterials is common; however, the incidence of surface deposition on the Vesair(®) intravesical pressure-attenuation balloon has not been previously reported. The purpose of this analysis is to determine the incidence and potential risk factors for encrustation of the Vesair intravesical balloon. METHODS: The SOLECT trial is a prospective randomized controlled trial conducted at several European centers to evaluate the safety and efficacy of the Vesair balloon for the treatment of female stress urinary incontinence (SUI)...
June 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28589404/erratum-to-secukinumab-is-efficacious-and-safe-in-hispanic-patients-with-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-four-phase-3-trials
#12
Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana
No abstract text is available yet for this article.
June 6, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28578501/monitoring-for-and-characterizing-crizotinib-progression-a-chart-review-of-alk-positive-non-small-cell-lung-cancer-patients
#13
Edmond Bendaly, Anand A Dalal, Kenneth Culver, Philip Galebach, Iryna Bocharova, Rebekah Foster, Medha Sasane, Alexander R Macalalad, Annie Guérin
INTRODUCTION: Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of second-generation ALK inhibitors, this study assessed how physicians monitor for and diagnose progression and how they alter treatment following progression on crizotinib. METHODS: A panel of oncologists from the United States were surveyed regarding their monitoring practices and criteria for diagnosing progression on crizotinib...
June 3, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28578500/real-world-impact-of-cardiovascular-disease-and-anemia-on-quality-of-life-and-productivity-in-patients-with-non-dialysis-dependent-chronic-kidney-disease
#14
Adrian Covic, James Jackson, Anna Hadfield, James Pike, Dimitrie Siriopol
INTRODUCTION: Patients with chronic kidney disease (CKD) have an increased risk of comorbid conditions, including cardiovascular disease (CVD). Anemia is prevalent in the CKD population and worsens as kidney function declines, resulting in a diminished quality of life and increased morbidity/mortality. The purpose of this secondary analysis was to determine the real-world prevalence of CVD among patients with non-dialysis-dependent CKD (NDD-CKD), with and without comorbid anemia, and to assess the impact of these conditions on quality of life (QoL) and work productivity...
June 3, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28573505/comparative-efficacy-of-ibrutinib-versus-obinutuzumab%C3%A2-%C3%A2-chlorambucil-in-first-line-treatment-of-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison
#15
Suzy Van Sanden, Simona Baculea, Joris Diels, Sarah Cote
INTRODUCTION: Ibrutinib (ibr) monotherapy and the combination of obinutuzumab plus chlorambucil (obi) are approved for previously untreated chronic lymphocytic leukemia (CLL). No trials directly comparing their efficacy are available. Therefore a matching-adjusted indirect comparison (MAIC) was performed to provide insight into their relative efficacy in terms of progression-free survival (PFS) and overall survival (OS). MAIC attempts to adjust for between-trial differences in factors known or suspected to influence treatment effects, to minimize bias...
June 1, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28608143/resource-utilization-among-glaucoma-patients-in-the-uk-treated-with-beta-blocker-and-non-beta-blocker-adjunctive-therapy-a-retrospective-cohort-analysis
#16
Ananth Viswanathan, Claudio Spera, Anmol Mullins, David Covert, Judit Banhazi, Paul McDwyer, Eibhlin Hudson, Alberto Ferreira
INTRODUCTION: Few studies have examined outcomes and potential complications among glaucoma patients who are prescribed topical beta-blockers. This study examined resource usage (number of GP visits and hospitalizations) and diagnoses of respiratory or cardiovascular conditions among glaucoma patients prescribed beta-blockers compared to patients not prescribed beta-blockers. METHODS: A retrospective cohort analysis was conducted using data from the UK Clinical Practice Research Datalink (CPRD) database over the period January 1, 2006 to March 31, 2014...
May 30, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28550638/erratum-to-evaluation-of-the-efficacy-of-sorafenib-on-overall-survival-in-patients-with-hepatocellular-carcinoma-using-ft-rate-a-devised-index
#17
Takamasa Ohki, Mayuko Kondo, Yuki Karasawa, Satoshi Kawamura, Shuuya Maeshima, Kentaro Kojima, Michiharu Seki, Nobuo Toda, Yoshinobu Shioda, Kazumi Tagawa
No abstract text is available yet for this article.
May 26, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28547734/systemic-therapy-for-soft-tissue-sarcoma-proposals-for-the-optimal-use-of-pazopanib-trabectedin-and-eribulin
#18
REVIEW
Akira Kawai, Kan Yonemori, Shunji Takahashi, Nobuhito Araki, Takafumi Ueda
Soft tissue sarcoma (STS) is a rare tumor with more than 50 histologic subtypes. Although treatment outcomes for patients with STS have improved greatly over the past few decades owing to the adoption of a multidisciplinary approach, patients with advanced disease have a poor prognosis. The development of anticancer drugs has been directed toward improving overall survival (OS). Doxorubicin monotherapy is currently the only standard option for the first-line treatment of STS. However, there is no standard therapy for second-line and later treatment at present...
May 25, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28540656/nalmefene-in-alcohol-use-disorder-subjects-with-psychiatric-comorbidity-a-naturalistic-study
#19
Marco Di Nicola, Sergio De Filippis, Giovanni Martinotti, Luisa De Risio, Mauro Pettorruso, Simone De Persis, Angelo Giovanni Icro Maremmani, Icro Maremmani, Massimo di Giannantonio, Luigi Janiri
INTRODUCTION: Nalmefene is the first drug to be approved for reducing alcohol consumption in alcohol use disorder (AUD) patients at high drinking risk. In real-world settings, there is a high prevalence of concurrent psychiatric disorders in AUD subjects, with associated increased morbidity and worse prognosis. This study evaluated the use of nalmefene in AUD patients with stabilized psychiatric comorbidity previously treated unsuccessfully for alcohol dependence, and assessed craving reduction and safety...
May 24, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28540655/a-review-of-subthreshold-micropulse-laser-for-treatment-of-macular-disorders
#20
REVIEW
Paula Scholz, Lebriz Altay, Sascha Fauser
Micropulse laser treatment is an alternative to the conventional continuous-wave laser for the treatment of retinal or macular diseases. In contrast to the conventional laser, the therapeutic effect of the subthreshold micropulse laser is not accompanied by thermal retinal damage. This fact is of particular importance when a treatment near the fovea is required. Micropulse treatment is applied in indications such as central serous chorioretinopathy (CSC), diabetic macular edema (DME), or macular edema due to retinal vein occlusion (RVO)...
May 24, 2017: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"